Jane Theaker
Chief Executive Officer, PBD Biotech
Jane Theaker is a companion diagnostics expert with a passion for using novel technologies, datasets and analytics to change the way we discover, develop and deliver drugs to patients. She has worked for the NHS, Zeneca Diagnostics, Astrazeneca, DxS, QIAGEN and the Laboratory of the Government Chemist (LGC). During her career Jane co-invented a real-time PCR technology at Zeneca Diagnostics that she and her team at QIAGEN later used to deliver FDA approved tests to support novel oncology drug launches. She was also an early proponent of NGS sequencing in Companion diagnostics. She is now the CEO of PBD Biotech, developers of Actiphage®, a phage-based test that identifies Mycobacterium tuberculosis (Mtb) in the blood – an early indication of ‘active’ TB disease. Actiphage has potential applications in latent TB screening and drug management.
